Takeya Sugimoto

Statistics

Publications

Citations

183

H-Index

Active since

2019

Affiliations

Wakayama Medical University(Current)

National Hospital Organization

Osaka International Cancer Institute

Osaka City General Hospital

Toneyama National Hospital

Takeya Sugimoto is an author at Wakayama Medical University specializing in oncology, non-small cell lung cancer treatment, and non-small cell lung cancer therapy.

Publications per year

2019–2022

Publications

Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer

Hiroaki Akamatsu, Eriko Murakami, Jun Oyanagi et al. · The Oncologist · 2019 · 79 citations · Full text

Life Sciences, Immunology, Oncology +17

Histologic transformation of epidermal growth factor receptor–mutated lung cancer

Daichi Fujimoto, Hiroaki Akamatsu, Takeshi Morimoto et al. · European Journal of Cancer · 2022 · 28 citations

Medicine, Oncology, Pathology +16

Osimertinib for patients with EGFR T790M mutation-positive non–small-cell lung cancer and a poor performance status

Kazuhisa Nakashima, Madoka Kimura, Hiroaki Akamatsu et al. · Japanese Journal of Clinical Oncology · 2019 · 22 citations

Medicine, Oncology, Pharmacology +16

CD24, not CD47, negatively impacts upon response to PD‐1/L1 inhibitors in non–small‐cell lung cancer with PD‐L1 tumor proportion score < 50

Yuichi Ozawa, Yuhei Harutani, Jun Oyanagi et al. · Cancer Science · 2020 · 16 citations · Full text

Life Sciences, Immunology, Oncology +17

Impact of pre‐existing interstitial lung abnormal shadow on lung injury development and severity in patients of non‐small cell lung cancer treated with osimertinib

Ryota Shibaki, Yuichi Ozawa, Susumu Noguchi et al. · Cancer Medicine · 2022 · 14 citations · Full text

Medicine, Oncology, Neoplasia +13

1–5 of 7